Use of Intralesional Verapamil to Dissolve Peyronie’s Disease Plaque: A Long-Term Single-Blind Study

Pathophysiology of Peyronie's disease

“…Verapamil, a calcium channel blocker, inhibits connective tissue synthesis in fibroblasts and has been shown to be effective in softening and dissolving plaques in the early stages of disease when injected into the plaques. 44,45 Colchicine, a microtubule polymerization inhibitor, also inhibits connective tissue synthesis in fibroblasts and has shown limited efficacy in Peyronie's disease patients when administered orally. 46 Initial trials of intra-plaque injection with collagenase have been disappointing.…”

Review of non-surgical treatment options for Peyronie's Disease

“…This group of investigators previously reported that 48% of patients had curvature progression in a no-treatment natural history observation study. 47 The first randomized, single-blind trial of intralesional verapamil was published in 1998 by Rehman et al 48 Significant improvements were noted in terms of erection [6][7][8][9][10][11][12][13][14][15][16][17][18], and all patients were treatmentnaive before entry into the study. Curvature was measured during duplex ultrasound of a pharmacologically induced erection.…”

Peyronie's disease: a critical appraisal of current diagnosis and treatment

“…Intralesional therapy was chosen during early studies because tissue concentrations necessary to exert an effect were 100-fold higher than safe serum levels. 32,80 In the first clinical trial evaluating intralesional verapamil vs placebo, 14 men with PD for more than 1 year were followed for 4-6 months after randomization. 32 Po0.01) relative to the verapamil with tamoxifen group.…”

“…32,80 In the first clinical trial evaluating intralesional verapamil vs placebo, 14 men with PD for more than 1 year were followed for 4-6 months after randomization. 32 Po0.01) relative to the verapamil with tamoxifen group. It has been hypothesized that the volume of verapamil injected is associated with the greatest benefit.…”